Treatment-Related Adverse Events
Cross-source consensus on Treatment-Related Adverse Events from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Benefits
Highlighted claims
- In MAPLE2, grade ≥3 adverse events within 3 months are evaluated by oncologists and nurses using NCI CTCAE V.5.0. — Feasibility of a mobile application-based geriatric assessment and communication support intervention for older adults with cancer: protocol for a pilot randomised controlled trial (MAPLE2 pilot)
- Patient-reported adverse events are measured using the 12 core symptom items from the NCI PRO-CTCAE, with the Japanese version linguistically and psychometrically validated. — Feasibility of a mobile application-based geriatric assessment and communication support intervention for older adults with cancer: protocol for a pilot randomised controlled trial (MAPLE2 pilot)
- Treatment modifications within 3 months — including dose reductions, switching from combination to monotherapy, or discontinuation — are tracked as a secondary health outcome. — Feasibility of a mobile application-based geriatric assessment and communication support intervention for older adults with cancer: protocol for a pilot randomised controlled trial (MAPLE2 pilot)
- In the prior MAPLE trial, grade ≥3 adverse events at 3 months occurred in 50.9% of the intervention arm compared with 66.4% of the usual care arm. — Feasibility of a mobile application-based geriatric assessment and communication support intervention for older adults with cancer: protocol for a pilot randomised controlled trial (MAPLE2 pilot)
- Grade ≥3 adverse events within 3 months is planned as the primary endpoint for the future definitive multicentre hybrid effectiveness-implementation RCT. — Feasibility of a mobile application-based geriatric assessment and communication support intervention for older adults with cancer: protocol for a pilot randomised controlled trial (MAPLE2 pilot)